Comment: Three RCTs have demonstrated that treatment with lusutrombopag, a thrombopoietin receptor agonist, significantly increased platelet count and reduced the need for platelet transfusions in patients with thrombocytopenia undergoing invasive procedures [181–183]. The gene discussed is MPL; the disease is Thrombocytopenia.